Bausch Health Companies (NYSE:BHC) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

Other research analysts have also recently issued reports about the company. Piper Jaffray Companies upgraded Bausch Health Companies from an “underweight” rating to a “neutral” rating and upped their price target for the stock from $16.00 to $19.00 in a research note on Thursday, September 13th. JPMorgan Chase & Co. upped their price target on Bausch Health Companies to $18.00 and gave the stock an “underweight” rating in a research note on Wednesday, August 8th. HC Wainwright restated a “hold” rating and set a $20.00 price target on shares of Bausch Health Companies in a research note on Friday, August 31st. BMO Capital Markets upped their price target on Bausch Health Companies from $20.00 to $22.00 and gave the stock a “market perform” rating in a research note on Monday, August 13th. Finally, Royal Bank of Canada upped their price target on Bausch Health Companies from $25.00 to $26.00 and gave the stock a “hold” rating in a research note on Wednesday, August 8th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $25.38.

NYSE:BHC opened at $24.78 on Monday. The company has a debt-to-equity ratio of 6.99, a quick ratio of 0.89 and a current ratio of 1.14. Bausch Health Companies has a 52 week low of $10.94 and a 52 week high of $27.79. The firm has a market cap of $8.71 billion, a price-to-earnings ratio of 6.47, a PEG ratio of 0.36 and a beta of -0.43.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Tuesday, August 7th. The company reported $0.93 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.12. Bausch Health Companies had a positive return on equity of 27.83% and a negative net margin of 20.60%. The company had revenue of $2.13 billion for the quarter, compared to analysts’ expectations of $2.05 billion. analysts anticipate that Bausch Health Companies will post 3.47 EPS for the current fiscal year.

In related news, Director Schutter Richard U. De acquired 125,000 shares of the business’s stock in a transaction dated Thursday, September 13th. The shares were acquired at an average price of $23.96 per share, with a total value of $2,995,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Joseph C. Papa acquired 30,000 shares of the business’s stock in a transaction dated Friday, September 14th. The shares were bought at an average cost of $22.32 per share, for a total transaction of $669,600.00. The disclosure for this purchase can be found here. Insiders have bought 165,000 shares of company stock worth $3,890,700 in the last ninety days. Corporate insiders own 11.54% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Point View Wealth Management Inc. purchased a new stake in shares of Bausch Health Companies during the second quarter worth $1,132,000. Marshall Wace LLP purchased a new stake in shares of Bausch Health Companies during the second quarter worth $2,974,000. Van ECK Associates Corp purchased a new stake in shares of Bausch Health Companies during the second quarter worth $11,494,000. Tobam purchased a new stake in shares of Bausch Health Companies during the second quarter worth $13,886,000. Finally, Private Management Group Inc. purchased a new stake in shares of Bausch Health Companies during the second quarter worth $28,474,000. 44.53% of the stock is currently owned by institutional investors and hedge funds.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

Featured Story: S&P 500 Index

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.